Stay updated with breaking news from Column Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
OpenAI’s corporate structure limits control from any of its shareholders.
/PRNewswire/ -- The "DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035" report has been added to ResearchAndMarkets.com's offering....
Key Insights Significantly high institutional ownership implies NGM Biopharmaceuticals' stock price is sensitive to...
Dr. McHutchison is a world-renowned physician, scientist, and drug developer who has led the research and development of numerous marketed therapies for...